Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
BOSTON, Feb. 05, 2016 -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced it will participate in multiple panel discussions at the 4th Annual Bloomberg Intelligence Healthcare Event on Friday, Feb. 12. The panels will begin at 1:30 pm ET and focus on the evolving strategies for biosimilars, as well as provide legal and regulatory updates on biosimilars.
The conference will be held on Friday, Feb. 12 starting at 8:30 am ET in New York City. Additional information is available at http://b.bloomberg.com/BIHealthCare-regsa. The link to the live audio webcast and replay of the presentation will be available through Bloomberg terminals at Live <go>.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS’ goal is to improve global patient access to important, cost-effective medicines. EPIRUS' current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)i. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets. For more information visit EPIRUS’ website at www.epirusbiopharma.com.
i Remicade is a registered trademark of Johnson and Johnson (www.jnj.com); Humira is a registered trademark of AbbVie (www.abbvie.com); Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group (www.gene.com); Stelara is owned and marketed by Centocor Ortho Biotech Inc, a wholly owned subsidiary of Johnson and Johnson (www.jnj.com); Simponi is marketed by Janssen Biotech Inc (www.janssenbiotech.com); Soliris is a registered trademark of Alexion Pharmaceuticals, Inc. (www.alxn.com)
Contact Information: For media inquiries: Hope Buggey, FleishmanHillard +1-919-336-3786 [email protected] For investor inquiries: Marek Ciszewski, J.D., EPIRUS Biopharmaceuticals +1-617-553-9716 [email protected]
